Ownership Summary
The institutional landscape for InMed Pharmaceuticals Inc. (NASDAQ:INM) includes 7 filers as of the latest reporting cycle ending December 2025.
- Institutional ownership in InMed Pharmaceuticals edged down to 9.8% in December 2025, compared to 23.8% in September 2025.
- Quarterly data indicates a 3.06% shift in institutional share volume, and the annual owner count reflects an increase of 16.67%.
- During the quarter, 3 institutions bought more InMed Pharmaceuticals shares, 1 sold shares, and 3 of the 7 total investors held their position steady.
- Collectively, institutional investors increased their stake in InMed Pharmaceuticals to 227.05K shares as of December 2025, a change that is up by 6.74K shares quarter on quarter and up 178.15K shares year over year.
- As of December 31, 2025, SABBY MANAGEMENT, LLC held InMed Pharmaceuticals's largest shareholding position with over 201.63K shares, representing 8.73% of total outstanding shares.
- Among the most significant buyers of InMed Pharmaceuticals during December 2025 were SUSQUEHANNA INTERNATIONAL GROUP, LLP (12.75K), JANE STREET GROUP, LLC (11.98K), UBS Group AG (377).
- Leading sellers of InMed Pharmaceuticals stock in December 2025 included SABBY MANAGEMENT, LLC (18.36K).
- The top 7 institutional holders of InMed Pharmaceuticals for the quarter ending December 2025 included SABBY MANAGEMENT, LLC (201.63K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (12.75K), JANE STREET GROUP, LLC (11.98K), UBS Group AG (377), SBI Securities Co., Ltd. (300), Banque Cantonale Vaudoise (6), Federation des caisses Desjardins du Quebec (1).